Ed Schoonveld

Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.

Providing evidence for a strong value proposition to each of the access journey decision makers needs to be weighed against the risk of clinical trial failure, cost of investment, and launch timing. Ed Schoonveld outlines how a pharma company can analyze and rejuvenate its decision process.

This article discusses how cost differences with other countries reflect income differences, how these differences are typical for cost in medical services, and more.

Ed Schoonveld reviews the key topics discussed at the World Health Organization's second Fair Pricing Forum, held in Johannesburg, South Africa last month.

We desperately need new anti-infective drugs to avoid life threatening infections. Let’s make that happen by punishing companies who don’t invest in R&D for these specific drugs.

Kaiser’s August healthcare poll results should put all on high alert given public sentiment and the rhetoric of the political season. Ed Schoonveld sounds the alarm and offers four initiatives to stall the surge towards government intercession on escalating prices.

Ed Schoonveld highlights the wait confronting lung cancer patients seeking Opdivo in the UK. Can we find room for compromise?

Positive early stage trial results for Biogen’s aducanumab has renewed hope for effective solutions for Alzheimer's Disease, but many challenges remain in finding and funding new treatment, writes Ed Schoonveld.

Recent developments in the pharmaceutical industry give the strong impression that both payers and industry are struggling to understand what represents “value” to customers, writes Ed Schoonveld.